Cargando…

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease

SIMPLE SUMMARY: Cytomegalovirus (CMV) infection and graft versus host disease (GVHD) both contribute to increased morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). Since the development of GVHD can increase a patient’s risk of developing CMV infection post-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolfe, Delaney, Zhao, Qiuhong, Siegel, Emma, Puto, Marcin, Murphy, Danielle, Roddy, Julianna, Efebera, Yvonne, Tossey, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583331/ https://www.ncbi.nlm.nih.gov/pubmed/34771734 http://dx.doi.org/10.3390/cancers13215572

Ejemplares similares

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
por: Sepassi, Aryana, et al.
Publicado: (2023)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
por: Xhemali, Xhilda, et al.
Publicado: (2023)

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
por: Derigs, Patrick, et al.
Publicado: (2020)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
por: Golan, Yoav, et al.
Publicado: (2021)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
por: Nho, Dukhee, et al.
Publicado: (2023)

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study
por: Schulte, Johannes H, et al.
Publicado: (2023)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis
por: Lauruschkat, Chris David, et al.
Publicado: (2023)

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients
por: Prohn, Marita, et al.
Publicado: (2021)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a35tr0hf1biiit2sqashjtuc7a